左卡尼汀治疗慢性心力衰竭的临床疗效分析(2)
 |
| 第1页 |
参见附件(3994KB，3页)。
[2] 殷仁富, 陈金明, 吴宗贵, 等.心脏能量学:代谢与治疗.上海:第二军医大学出版社, 2002,80.
[3] Gueertl B, Nohammer C, Hoefler G, et al. Metabolic cardiomyopathies. Int J Exp Pathol, 2000, 81(6):349-372.
[4] Rizos I. Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration.Am Heart J, 2000,139 (2):120-123.
[5] 刘培良, 袁龙, 赵政凯, 等. 左旋卡尼汀合并坎地沙坦治疗慢性心力衰竭疗效及安全性临床观察. 中国实用医药, 2008,82 (7):97-99.
[6] Schofield RS, Hill JA. Role of metabolically active drugs in management of ischemic heart disease. Am J Cardiovasc Drugs, 2001,1(1):23-35.
[7] Reda E, D'Iddio S, Nicolai R, et al. The carnitine system and body composition. Acta Diabetol, 2003,40(Suppl 1):S106-113.
[8] R Lango, RT Smolenski, M Narkiewicz, et a1. Influence of L-carnitine and its derivatives on myocardial metabolism and function in isehemic heart disease and during cardiopulmonary bypass .Cardiovase Res, 200l,5l(1):21-29.
[9] 卢福建. 左旋左卡尼汀治疗急性病毒性心肌炎30例. 临床医学, 2008,28(9):71-72.
[10]吴学华, 胡华伟. 左卡尼汀治疗慢性充血性心力衰竭疗效观察. 实用中西医结合临床, 2008,8(4):15-16.
[11] 陈朝婷, 陈祥华, 胡萍, 等. 左卡尼汀治疗老年慢性心力衰竭的疗效和安全性. 中国心血管病研究, 2007,5(9):649-651.
您现在查看是摘要介绍页，详见PDF附件(3994KB，3页)。